Hard-fought approval to commercial flop: Uniqure pulling plug on first gene therapy
LONDON Uniqure NV is ditching its world-first gene therapy Glybera and will not renew the European license when it expires on Oct. 25. If that is a sad end to one of the most protracted drug development sagas in history, it undoubtedly sets a bad precedent for expensive one-off therapies coming through the pipeline for which Uniqure's persistence with the EMA did so much to forge the way.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST